Application of nanomedicine to cross BBB Nanoparticles (NPs) are primarily defined as ultrafine particles with sizes ranging from 1 to 100 nanometers and NPs have been explored for a vast range of applications in agriculture, textiles, cosmetics, food and petroleum production, electronics, and in many other areas, including medicine. In all cases, an effective NP ensures its biodegradability, stability, high loading capacity, and efficient release. Andreas Aslund, anchored at SINTEF BTN, is involved in several high-profile applications of nanomedicine in cancer. His work has directly contributed to a biotech start-up, Nadeno. Andreas Aslund is collaborating with Hilde Nilsen and Deo Pandey to package the small molecules generated in their laboratories as nanoparticles. These NPs will be tested for their efficacy in the disease models present in the laboratories of Hilde Nilsen, Deo Pandey and Johanne Egge Rinholm and subsequently evaluated for their ability to cross the BBB. 

Application of nanomedicine to cross BBB Nanoparticles (NPs) are primarily defined as ultrafine particles with sizes ranging from 1 to 100 nanometers and NPs have been explored for a vast range of applications in agriculture, textiles, cosmetics, food and petroleum production, electronics, and in many other areas, including medicine. In all cases, an effective NP ensures its biodegradability, stability, high loading capacity, and efficient release. Andreas Aslund, anchored at SINTEF BTN, is involved in several high-profile applications of nanomedicine in cancer. His work has directly contributed to a biotech start-up, Nadeno. Andreas Aslund is collaborating with Hilde Nilsen and Deo Pandey to package the small molecules generated in their laboratories as nanoparticles. These NPs will be tested for their efficacy in the disease models present in the laboratories of Hilde Nilsen, Deo Pandey and Johanne Egge Rinholm and subsequently evaluated for their ability to cross the BBB.